[{"id":1,"text":"Data from deep sequencing of a Ph-negative clone of a Ph-positive CML patient has found a driving mutation in DNMT3A that preceeded the BCR-ABL fusion, and may imply the possibility that BCR-ABL is not universally the initiating event in CML.","disease":"Chronic Myeloid Leukemia","doid":"8552","citation":"Schmidt et al., 2014, Leukemia","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/25212276","pubmed_id":"25212276","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":2,"evidence_level":"C","evidence_type":"Diagnostic","clinical_significance":"Positive","evidence_direction":"Does Not Support","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":2,"text":"The presence of BCR-ABL fusion is considered the characterizing feature of chronic myeloid leukemia, and has been widely thought of as the initiating event in the disease.","disease":"Chronic Myeloid Leukemia","doid":"8552","citation":"An et al., 2010, Leuk. Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/20537386","pubmed_id":"20537386","drugs":[{"id":1,"name":"N/A","pubchem_id":null}],"rating":4,"evidence_level":"A","evidence_type":"Diagnostic","clinical_significance":"Positive","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":3,"text":"The use of second-generation BCR-ABL targeted therapies has been effective in patients resistant to imatinib.","disease":"Chronic Myeloid Leukemia","doid":"8552","citation":"An et al., 2010, Leuk. Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/20537386","pubmed_id":"20537386","drugs":[{"id":2,"name":"Nilotinib","pubchem_id":null},{"id":3,"name":"Dasatinib","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":4,"text":"COS7 cell lines transfected with BCR/ABL constructs harboring E255K mutations were shown to be resistant to imatinib and exhibited increased kinase activity.","disease":"Chronic Myeloid Leukemia","doid":"8552","citation":"Yamamoto et al., 2004, Biochem. Biophys. Res. Commun.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/15194504","pubmed_id":"15194504","drugs":[{"id":4,"name":"Imatinib","pubchem_id":null}],"rating":4,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":5,"text":"COS7 cell lines transfected with BCR/ABL constructs harboring T315I mutations were shown to be resistant to imatinib and exhibited increased kinase activity.","disease":"Chronic Myeloid Leukemia","doid":"8552","citation":"Yamamoto et al., 2004, Biochem. Biophys. Res. Commun.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/15194504","pubmed_id":"15194504","drugs":[{"id":4,"name":"Imatinib","pubchem_id":null}],"rating":4,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":6,"text":"In chronic myeloid leukemia patients with the ABL T315I mutation, tumors have shown to be resistant to imatinib treatment.","disease":"Chronic Myeloid Leukemia","doid":"8552","citation":"An et al., 2010, Leuk. Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/20537386","pubmed_id":"20537386","drugs":[{"id":4,"name":"Imatinib","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":7,"text":"PIK3CA mutation, but not AKT1 E17K, has been shown to confer sensitiity to the AKT inhibitor MK-2206 in breast cancer cell lines.","disease":"Breast Cancer","doid":"1612","citation":"Beaver et al., 2013, Clin. Cancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23888070","pubmed_id":"23888070","drugs":[{"id":5,"name":"MK-2206","pubchem_id":null}],"rating":3,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Does Not Support","variant_hgvs":"14:105246551-105246551 (C-\u003eT)","variant_origin":"Somatic"},{"id":8,"text":"In patients with non-small cell lung cancer harboring the EML4-ALK fusion, treatment with crizotinib has shown to be effective in acheiving stable disease.","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Choi et al., 2010, N. Engl. J. Med.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/20979473","pubmed_id":"20979473","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":9,"text":"In patients with non-small cell lung cancer harboring EML4-ALK fusion, the C1156Y variant has been shown to confer resistance to crizotinib.","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Choi et al., 2010, N. Engl. J. Med.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/20979473","pubmed_id":"20979473","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":10,"text":"CH5424802 treatment resulted in significant tumor regression in xenograft models produced from Ba/F3 cells expressing EML4-ALK or AML4-ALK with the L1196M mutation","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Sakamoto et al., 2011, Cancer Cell","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21575866","pubmed_id":"21575866","drugs":[{"id":7,"name":"CH5424802","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":11,"text":"In patients with non-small cell lung cancer harboring EML4-ALK fusion, the L1196M variant has been shown to confer resistance to crizotinib.","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Choi et al., 2010, N. Engl. J. Med.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/20979473","pubmed_id":"20979473","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":12,"text":"Ba/F3 cells expressing the RANBP2-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing RANBP2-ALK without this mutation.","disease":"Inflammatory Myofibroblastic Tumor","doid":"0050905","citation":"Sasaki et al., 2010, Cancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21030459","pubmed_id":"21030459","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"2:29443695-29443695 (G-\u003eT)","variant_origin":"Somatic"},{"id":13,"text":"CH5424802 is effective in inhibiting the activity of the F1174L ALK mutant in a kinase activity assay and proliferation assay using neuroblastoma KELLY cells.","disease":"Neuroblastoma","doid":"769","citation":"Sakamoto et al., 2011, Cancer Cell","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21575866","pubmed_id":"21575866","drugs":[{"id":7,"name":"CH5424802","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"2:29443695-29443695 (G-\u003eT)","variant_origin":"Somatic"},{"id":14,"text":"Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation.","disease":"Neuroblastoma","doid":"769","citation":"Bresler et al., 2011, Sci Transl Med","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/22072639","pubmed_id":"22072639","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"2:29443695-29443695 (G-\u003eT)","variant_origin":"Somatic"},{"id":15,"text":"High levels of crizotinib can overcome drug resistance of Ba/F3 cells expressing the EML4-ALK fusion containing the F1174L mutation.","disease":"Neuroblastoma","doid":"769","citation":"Heuckmann et al., 2011, Clin. Cancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21948233","pubmed_id":"21948233","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"2:29443695-29443695 (G-\u003eT)","variant_origin":"Somatic"},{"id":16,"text":"SH-SY5Y and Kelly cells with mutant ALK (F1174L) and Ba/F3 cells overexpressing ALK harboring the F1174L mutation are sensitive to TAE684-mediated growth inhibition","disease":"Neuroblastoma","doid":"769","citation":"George et al., 2008, Nature","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/18923525","pubmed_id":"18923525","drugs":[{"id":8,"name":"TAE684","pubchem_id":null}],"rating":4,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"2:29443695-29443695 (G-\u003eT)","variant_origin":"Somatic"},{"id":17,"text":"Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK without this mutation.","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Sasaki et al., 2010, Cancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21030459","pubmed_id":"21030459","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"2:29443695-29443695 (G-\u003eT)","variant_origin":"Somatic"},{"id":18,"text":"Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation","disease":"Neuroblastoma","doid":"769","citation":"Bresler et al., 2011, Sci Transl Med","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/22072639","pubmed_id":"22072639","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"2:29432664-29432664 (C-\u003eT)","variant_origin":"Somatic"},{"id":19,"text":"TAE684 inhibits growth of Ba/F3 cells expressing ALK mutations; however, cells with the R1275Q mutation were inhibited at a higher IC50 than those expressing F1174L.","disease":"Neuroblastoma","doid":"769","citation":"George et al., 2008, Nature","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/18923525","pubmed_id":"18923525","drugs":[{"id":8,"name":"TAE684","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"2:29432664-29432664 (C-\u003eT)","variant_origin":"Somatic"},{"id":20,"text":"The SMS-KCNR cell line harboring the R1275Q mutation was resistant to TAE684.","disease":"Neuroblastoma","doid":"769","citation":"George et al., 2008, Nature","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/18923525","pubmed_id":"18923525","drugs":[{"id":8,"name":"TAE684","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"2:29432664-29432664 (C-\u003eT)","variant_origin":"Somatic"},{"id":21,"text":"In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission.","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Imielinski et al., 2014, J. Clin. Invest.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/24569458","pubmed_id":"24569458","drugs":[{"id":9,"name":"Sorafenib","pubchem_id":null}],"rating":2,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"X:47426121-47426121 (C-\u003eG)","variant_origin":"Somatic"},{"id":22,"text":"Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Imielinski et al., 2014, J. Clin. Invest.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/24569458","pubmed_id":"24569458","drugs":[{"id":9,"name":"Sorafenib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"X:47426121-47426121 (C-\u003eG)","variant_origin":"Somatic"},{"id":23,"text":"Trametinib can inhibit ARF-mediated ERK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Imielinski et al., 2014, J. Clin. Invest.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/24569458","pubmed_id":"24569458","drugs":[{"id":10,"name":"Trametinib","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"X:47426121-47426121 (C-\u003eG)","variant_origin":"Somatic"},{"id":24,"text":"In metastatic colorectal cancer patients with wildtype KRAS, BRAF mutations were associated with poor progression free survival regardless of treatment (panitumumab with best supportive care or best supportive care alone)","disease":"Colorectal Cancer","doid":"9256","citation":"Peeters et al., 2013, Clin. Cancer Res.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23325582","pubmed_id":"23325582","drugs":[{"id":11,"name":"Panitumumab","pubchem_id":null}],"rating":3,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":25,"text":"Melanoma patients with BRAF V600E/K mutations had longer progression-free survival, increased tumor regression,  and increased duration of response to combined dabrafenib and trametinib treatment compared to dabrafenib alone","disease":"Melanoma","doid":"1909","citation":"Flaherty et al., 2012, N. Engl. J. Med.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23020132","pubmed_id":"23020132","drugs":[{"id":12,"name":"Dabrafenib","pubchem_id":null},{"id":10,"name":"Trametinib","pubchem_id":null}],"rating":3,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}]